| Objective: Myelosuppression is a common adverse effect of chemotherapy in patients with bone and soft tissue sarcoma.It is often manifested by varying degrees of decline in peripheral blood cell count,which often leads to a decline in patients’ quality of life,reduced chemotherapy tolerance,and even the interruption of chemotherapy treatment.Traditional Chinese medicine therapy has the effect of overall regulation of the body.In this study,combined with the experience in clinical practice,Yi Sui Sheng Xue prescription was designed to prevent and treat myelosuppression caused by chemotherapy in patients with bone and soft tissue sarcoma,so as to improve the clinical symptoms of tumor patients,strengthen the stability of chemotherapy course,and provide research ideas and methods for the treatment of myelosuppression in patients with bone and soft tissue sarcoma after chemotherapy.In order to play a role in clinical practice.Data and METHODS: Patients with primary bone and soft tissue sarcoma admitted to the Department of Bone and Soft Tissue Oncology,Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from December 2021 to December 2022 were selected,including osteosarcoma and Ewing’s sarcoma,the most common malignant bone tumors,as well as undifferentiated pleomorphic sarcoma and synovial sarcoma,which are common in soft tissue sarcoma.A total of 58 patients were included in the study.58 patients were divided into treatment group(29 cases)(Yi Sui Sheng Xue formula combined with chemotherapy)and control group(29 cases)(chemotherapy regimen alone).Chemotherapy regimen in both groups was carried out according to conventional chemotherapy regimen.The control group was treated with chemotherapy alone,and the treatment group was given Yi Sui Sheng Xue prescription,one dose a day,twice a day,on the first day of chemotherapy for 14 days.Observation was made on the peripheral blood cell count in both the treatment and control groups,with the aim of reducing repetition on the day before chemotherapy and on the 7th,10 th and 14 th day after chemotherapy,respectively,and the changes of peripheral blood white blood cell count(WBC),neutrophil count(neutrophil),hemoglobin(Hb)count and platelet count(PLT)were compared between the two groups.The quality of life KPS score and TCM syndrome score The pre-and posttreatment records of both groups were compared.Results:1.In the randomized controlled study of 58 patients with bone and soft tissue sarcoma undergoing chemotherapy,there was no significant difference between the two groups in terms of baseline conditions,so they were comparable(P > 0.05);2.Comparison of the occurrence of myelosuppression: Before treatment,there was no significant difference between the two groups(P > 0.05).After treatment,the peripheral blood cell count decreased in both the treatment group and the control group,but the levels of neutrophils,leukocytes,hemoglobin and platelets in the treatment group were significantly higher than those in the control group,and the difference was statistically significant.3.Comparison of KPS score of quality of life: Before treatment,there was comparability between the two groups of patients.After treatment,the decline rate of the treatment group was significantly lower than that of the control group,and the difference was significant(P < 0.05);4.After treatment,TCM syndrome scores in both groups showed a downward trend,and TCM syndrome scores in the treatment group were higher than those in the control group,the difference was statistically significant;5.Safety analysis: electrocardiogram,liver and kidney function of patients in the treatment group and the control group were not significantly abnormal,and no obvious toxic and side effects were observed.Conclusion:1.This study showed that taking the self-designed Yi Sui Sheng Xue formula during chemotherapy could significantly reduce the incidence and degree of myelosuppression after chemotherapy for bone and soft tissue sarcoma,and effectively reduce the decline range of KPS scores after chemotherapy for malignant tumor patients,improve the quality of life,and improve patients’ TCM syndrome scores.It is worthy of further popularization and application in patients with malignant tumor.2.In the course of chemotherapy for patients with bone and soft tissue sarcoma,the adjuvant treatment of Chinese medicine can effectively improve the clinical symptoms of patients,enhance immunity,the clinical efficacy is safe and stable,can play a synergistic and toxic effect,and has a significant role in improving patients’ tolerance to chemotherapy course.3.In the treatment of bone and soft tissue sarcoma,It is important to consider the synergistic effects of traditional Chinese medicine and chemotherapy in order to minimize the adverse effects of treatment.This approach can lead to an improvement in patients’ overall survival rate enhance patients’ immunity,improve patients’ chemotherapy tolerance. |
PDF Full Text Request